MX341578B - Tratamiento de la osteoartritis y del dolor. - Google Patents

Tratamiento de la osteoartritis y del dolor.

Info

Publication number
MX341578B
MX341578B MX2013009130A MX2013009130A MX341578B MX 341578 B MX341578 B MX 341578B MX 2013009130 A MX2013009130 A MX 2013009130A MX 2013009130 A MX2013009130 A MX 2013009130A MX 341578 B MX341578 B MX 341578B
Authority
MX
Mexico
Prior art keywords
osteoarthritis
pain
treatment
binding proteins
multispecific
Prior art date
Application number
MX2013009130A
Other languages
English (en)
Other versions
MX2013009130A (es
Inventor
V Kamath Rajesh
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2013009130A publication Critical patent/MX2013009130A/es
Publication of MX341578B publication Critical patent/MX341578B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a una proteína de unión que se une tanto IL-1ß para usarse en el tratamiento de osteoartritis en un individuo que padece de osteoartritis, en donde la proteína de unión es una proteína de unión de dominio variable dual de inmunoglobulina (DVD-Ig) que se une tanto a IL-1? como a IL-1ß y trata la osteoartritis. Figura 1 y 2.
MX2013009130A 2011-02-08 2012-02-08 Tratamiento de la osteoartritis y del dolor. MX341578B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161440853P 2011-02-08 2011-02-08
PCT/US2012/024356 WO2012109373A2 (en) 2011-02-08 2012-02-08 Treatment of osteoarthritis and pain

Publications (2)

Publication Number Publication Date
MX2013009130A MX2013009130A (es) 2014-07-09
MX341578B true MX341578B (es) 2016-08-25

Family

ID=46600758

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013009130A MX341578B (es) 2011-02-08 2012-02-08 Tratamiento de la osteoartritis y del dolor.

Country Status (19)

Country Link
US (2) US8889130B2 (es)
EP (1) EP2672997A4 (es)
JP (2) JP5918275B2 (es)
KR (2) KR20130130825A (es)
CN (2) CN105749286A (es)
AU (2) AU2012214449B2 (es)
BR (1) BR112013020259A2 (es)
CA (1) CA2826564C (es)
CL (2) CL2013002298A1 (es)
CO (1) CO6751274A2 (es)
DO (2) DOP2013000178A (es)
IL (1) IL227771A0 (es)
MX (1) MX341578B (es)
PH (1) PH12013501636A1 (es)
RU (2) RU2015134562A (es)
SG (1) SG192694A1 (es)
TW (2) TW201527322A (es)
UA (1) UA110049C2 (es)
WO (1) WO2012109373A2 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
MX336152B (es) 2009-08-29 2016-01-08 Abbvie Inc Proteinas terapeutico de union a dll4.
EP3072904A1 (en) 2010-03-02 2016-09-28 Abbvie Inc. Therapeutic dll4 binding proteins
EP3252072A3 (en) 2010-08-03 2018-03-14 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
MY171664A (en) 2012-11-01 2019-10-22 Abbvie Inc Anti-dll4/vegf dual variable domain immunoglobulins and uses thereof
CA2931978A1 (en) * 2013-12-02 2015-06-11 Abbvie Inc. Compositions and methods for treating osteoarthritis
KR101587412B1 (ko) * 2014-10-17 2016-01-21 주식회사 휴온스 사이클로스포린 및 트레할로스를 포함하는 안과용 조성물
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
AU2016312510A1 (en) * 2015-08-25 2018-03-08 Armo Biosciences, Inc. Methods of using Interleukin-10 for treating diseases and disorders
CN105106490A (zh) * 2015-09-02 2015-12-02 济南舜昊生物科技有限公司 一种治疗小儿髋关节积液的药物及其制备方法
JP6592600B2 (ja) * 2015-10-30 2019-10-16 イーライ リリー アンド カンパニー 抗ｃｇｒｐ／抗ｉｌ−２３二重特異性抗体及びその使用
WO2017123934A1 (en) * 2016-01-13 2017-07-20 Merial, Inc. Recombinant aav vectors expressing osteoprotective genes, including has2 and lubricin, useful in the treatment of osteoarthritis and related joint conditions in mammals
KR20250011248A (ko) 2016-03-11 2025-01-21 스칼러 락, 인크. TGFβ1-결합 이뮤노글로불린 및 그의 용도
KR20230130155A (ko) 2016-08-19 2023-09-11 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 재조합 자기-상보적인 아데노-부속 바이러스를 이용한 병태의 치료 방법 및 조성물
BR112019008788A2 (pt) * 2016-10-31 2019-07-16 Kolon Life Science, Inc. composição para aliviar ou tratar a dor
CN106390099A (zh) * 2016-11-07 2017-02-15 广州赛莱拉干细胞科技股份有限公司 一种牙髓干细胞组合物及其应用
WO2018106956A2 (en) 2016-12-07 2018-06-14 University Of Florida Research Foundation, Incorporated IL-1RA CDNAs
BR112019013908A2 (pt) * 2017-01-06 2020-02-04 Scholar Rock, Inc. inibidores de tgfss1 isoforma-específicos, contexto-permissivos, e seus usos
TWI671761B (zh) * 2017-05-01 2019-09-11 臺中榮民總醫院 脊椎關節炎患者疾病活動度電子病歷管理系統
CN113164430A (zh) * 2018-06-03 2021-07-23 格莱科米拉治疗公司 用于在暴露于电离辐射和/或化学疗法之后预防严重健康后果和/或组织损伤的方法
CN110652502A (zh) * 2018-06-28 2020-01-07 复旦大学 一种靶向治疗类风湿关节炎的药物组合物
CN110818793A (zh) 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
WO2020176478A1 (en) 2019-02-25 2020-09-03 The University Of Chicago Methods and compositions for treating inflammatory and autoimmune conditions with ecm-affinity peptides linked to anti-inflammatory agents
IL288024B2 (en) 2019-05-14 2025-12-01 Provention Bio Inc Methods and compositions for preventing type
UA128416C2 (uk) * 2019-08-15 2024-07-03 Генмаб А/С Фармацевтичні композиції, які містять біспецифічні антитіла проти cd3 і cd20, та їх застосування
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
TWI789123B (zh) * 2021-11-17 2023-01-01 樂濎生醫股份有限公司 使用生長因子來治療關節炎
CN116836291B (zh) * 2023-08-25 2023-11-07 宝船生物医药科技(上海)有限公司 抗cd47-cldn18.2双特异性抗体的抗独特型抗体及其制备方法和应用
CN119970627B (zh) * 2025-04-15 2025-06-17 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） 用于骨关节炎修复的温敏控释水凝胶复合材料及制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2286388C2 (ru) * 1988-05-27 2006-10-27 Амген Инк. Ингибитор интерлейкина-1, способ его получения, молекула днк, кодирующая ингибитор интерлейкина-1 и его предшественник
DE69739656D1 (de) * 1996-02-09 2009-12-31 Amgen Inc 1 inhibitor und hyaluronan als polymer mit verzögerter wirkstofffreigabe
EP1200127B1 (en) * 1999-07-21 2008-06-25 Omeros Corporation Solutions and methods for inhibition of pain, inflammation and cartilage degradation
CN101525384A (zh) 2000-06-29 2009-09-09 艾博特公司 双特异性抗体及其制备方法和用途
AU2003208946A1 (en) * 2002-02-28 2003-09-16 Eli Lilly And Company Anti-interleukin-1 beta analogs
ME00204B (me) * 2002-09-06 2011-02-10 Medarex Llc Terapijsko, humano, monoklonsko anti-il-1r1antitijelo
ES2567198T3 (es) * 2003-01-24 2016-04-20 Applied Molecular Evolution, Inc. Antagonistas de la IL-1 beta humana
WO2005080429A2 (en) * 2004-02-11 2005-09-01 Warner-Lambert Company Llc Methods of treating osteoarthritis with anti-il-6 or anti-il6 receptor antibodies
EP2163562B1 (en) 2005-06-21 2013-09-18 XOMA Technology Ltd. IL-1beta binding antibodies and fragments thereof
US20090215992A1 (en) 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
EP2500352A1 (en) * 2005-08-19 2012-09-19 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US7695718B2 (en) * 2006-12-20 2010-04-13 Xoma Technology Ltd. Methods for the treatment of IL-1β related diseases
WO2008082651A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Dual-specific il-1a/ il-1b antibodies
JP2011523853A (ja) * 2008-06-03 2011-08-25 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリン及びその使用
SG172855A1 (en) 2009-01-29 2011-08-29 Abbott Lab Il-1 binding proteins
US20110165063A1 (en) 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
AU2010242840B2 (en) * 2009-05-01 2014-04-17 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CN102655880A (zh) 2009-10-15 2012-09-05 雅培制药有限公司 Il-1结合蛋白
MY161302A (en) * 2010-05-14 2017-04-14 Abbvie Inc IL-1 binding proteins
EP3301195B1 (en) 2010-07-12 2022-11-02 Gen-Probe Incorporated Compositions and assays to detect 2009 swine h1n1 influenza a virus nucleic acid
TW201307388A (zh) 2010-12-21 2013-02-16 Abbott Lab Ｉｌ－１結合蛋白
CA2856582A1 (en) * 2011-11-21 2013-05-30 Abbvie Inc. Il-1 binding proteins

Also Published As

Publication number Publication date
EP2672997A2 (en) 2013-12-18
DOP2016000114A (es) 2016-06-15
TW201307389A (zh) 2013-02-16
PH12013501636A1 (en) 2013-10-14
WO2012109373A2 (en) 2012-08-16
US20150050238A1 (en) 2015-02-19
NZ614207A (en) 2015-12-24
RU2015134562A3 (es) 2018-12-24
CO6751274A2 (es) 2013-09-16
JP2014507434A (ja) 2014-03-27
RU2563830C2 (ru) 2015-09-20
KR20130130825A (ko) 2013-12-02
BR112013020259A2 (pt) 2018-05-15
CN103596591A (zh) 2014-02-19
AU2012214449A1 (en) 2013-05-02
TWI531377B (zh) 2016-05-01
RU2013141211A (ru) 2015-03-20
RU2015134562A (ru) 2018-12-24
CL2016000530A1 (es) 2016-12-02
US8889130B2 (en) 2014-11-18
MX2013009130A (es) 2014-07-09
CA2826564C (en) 2018-05-15
CN103596591B (zh) 2016-08-24
CN105749286A (zh) 2016-07-13
DOP2013000178A (es) 2014-06-30
SG192694A1 (en) 2013-09-30
TW201527322A (zh) 2015-07-16
EP2672997A4 (en) 2015-05-06
CL2013002298A1 (es) 2014-08-08
KR20150080033A (ko) 2015-07-08
JP5918275B2 (ja) 2016-05-18
CA2826564A1 (en) 2012-08-16
AU2012214449B2 (en) 2016-07-07
WO2012109373A3 (en) 2012-11-01
UA110049C2 (uk) 2015-11-10
US20120201781A1 (en) 2012-08-09
AU2016203917A1 (en) 2016-07-07
IL227771A0 (en) 2013-09-30
JP2016106086A (ja) 2016-06-16

Similar Documents

Publication Publication Date Title
MX341578B (es) Tratamiento de la osteoartritis y del dolor.
PH12018500452A1 (en) Novel modulators and methods of use
PH12012502523A1 (en) Dual variable domain immunoglobulins and uses thereof
TN2014000206A1 (en) Antibody molecules having specificity for human ox40
PH12017500864A1 (en) Anti-notch1 antibodies
PH12017501139A1 (en) Novel modulators and methods of use
PH12014500903A1 (en) Bispecific immunobinders directed against tnf and il-17
PH12014501108A1 (en) Anti-il-36r antibodies
PH12014501427B1 (en) Anti-phf-tau antibodies and their uses
TW201206473A (en) Dual variable domain immunoglobulins and uses thereof
PH12013500337A1 (en) Dual variable domain immunoglobulins and uses thereof
PH12013500867A1 (en) Dual variable domain immunoglobulins and uses thereof
SG178602A1 (en) Dual variable domain immunoglobulins and uses thereof
PH12012500774A1 (en) Dual variable domain immunoglobulins and uses thereof
PH12012500815A1 (en) Dual variable domain immunoglobulins and uses thereof
MX2012004415A (es) Inmunoglobulinas de dominio variable doble y usos de las mismas.
MX2012001262A (es) Inmunoglobulinas de dominio variable doble y usos de las misma.
MX2011011669A (es) Inmunoglobulinas de dominio variable dual y usos de las misma.
EA201101303A1 (ru) Молекулы антител, обладающие связывающей специфичностью в отношении il-13 человека
IN2015DN00636A (es)
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
MX2022000242A (es) Anticuerpos contra ticagrelor y metodos de uso.
WO2012166659A3 (en) Anti-emr1 antibodies
WO2012119045A3 (en) Compositions and uses thereof to ameliorate pain
PH12014502075A1 (en) Use of (rs)-s-cyclopropyl-s-(4-{[4-{[1r, 2r)-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treating specific tumours

Legal Events

Date Code Title Description
FG Grant or registration